Yvonne McCall
Medical · Peoria, ILNPI 1922168293
Payments from drug & device makers
Across 68 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$321
- Gilead$244
- Abbott$184
- Dexcom, Inc.$130
- Bayer$64
- Xeris Pharmaceuticals, Inc.$60
- plus $370 from 14 others
What the payments were for
- Food & beverage$1,374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $321 |
| Gilead | 15 | $244 |
| Abbott | 9 | $184 |
| Dexcom, Inc. | 2 | $130 |
| Bayer | 4 | $64 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Medtronic | 1 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Pfizer | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Novo Nordisk | 2 | $30 |
| Lilly USA, LLC | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Merck | 1 | $24 |
| GSK | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,374 in reported general payments places this provider in the 70th percentile of 449 medical providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 43 | $40,749 |
| OzempicSemaglutide | 33 | $29,189 |
| EliquisApixaban | 33 | $22,871 |
| MounjaroTirzepatide | 12 | $14,391 |
| AtivanLorazepam | 12 | $11,932 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $9,233 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $9,223 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $5,223 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,142 |
| Pregabalin | 43 | $4,896 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,786 |
| Gabapentin | 202 | $2,429 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 100 | $2,211 |
| Omeprazole | 178 | $1,969 |
| Atorvastatin Calcium | 228 | $1,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $30 | $29,18933 claims |
| PfizerEliquis | $37 | $22,87133 claims |
| Lilly USA, LLCMounjaro | $27 | $14,39112 claims |
| GSKIncruse Ellipta | $23 | $9,23328 claims |
| AstraZenecaSymbicort | $12 | $5,14213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 449 medical providers in Illinois.
Other medical in Peoria
- Laura Wilson BrownPeoria$5K
- Andrea TurekChicago$145K
- Priya BediElmhurst$56K
- Jennifer GarsonChicago$32K
- Bernice JohnsonPalos Heights$32K
- William KvasnickaChicago$19K
- Katie SpringerLake Forest$17K
- Matthew BrunoMorris$17K
- Kelly BrawleyBarrington$14K
- Megan GriggsSpringfield$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.